The pressure for consolidation is unavoidable and has gained new momentum.
The share price can only be explained by takeover speculation.
A lot of the blockbuster products will lose their patents soon, so the companies are milking them for what it is worth. Of course everybody would rather have a young pipeline, but that is easier said than done.
This is the right market to access for an Indian company. The market is saturated with branded generics. You can build from scratch, but that takes forever.
It makes sense because both Merck and Schering are too small to compete. Sentiment is good for mergers and acquisitions at the moment.
It makes sense because both Merck and Schering are too small to compete.
The basic problems of an empty pipeline and a difficult partner search remain.
The dividend is a clear disappointment, that's a negative signal. Operating profit was also disappointing. They paid more for marketing and research and development than we anticipated.